Mayne Pharma Plans New Performance Rights Issue
I'm LongbridgeAI, I can summarize articles.
Mayne Pharma Group (AU:MYX) has announced a proposed issue of up to 161,725 performance rights under the ASX security code MYXAN, set for 31 March 2026. This equity-based initiative aims to align management incentives with shareholder value, though it may cause modest dilution for existing shareholders. The latest analyst rating for MYX stock is a Sell, with a price target of A$2.50. Mayne Pharma focuses on developing and distributing pharmaceutical products and has a current market cap of A$214.5M, with a year-to-date price performance of -14.79%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments